Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763404 | PMC |
| http://dx.doi.org/10.1002/hon.2320 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: J-Lat cells are derivatives of the Jurkat CD4+ T cell line that contain a non-infectious, inducible HIV provirus with a GFP tag. While these cells have substantially advanced our understanding of HIV latency, their use by many laboratories in low and middle-income countries is restricted by limited access to flow cytometry. To overcome this barrier, we describe a modified J-Lat assay using a standard microplate reader that detects HIV-GFP expression following treatment with latency-reversing agents (LRAs).
View Article and Find Full Text PDFPAK1 inhibition with Romidepsin attenuates H-reflex hyperexcitability after spinal cord injury.
J Physiol
October 2024
Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, CT, USA.
Hyperreflexia associated with spasticity is a prevalent neurological condition characterized by excessive and exaggerated reflex responses to stimuli. Hyperreflexia can be caused by several diseases including multiple sclerosis, stroke and spinal cord injury (SCI). Although we have previously identified the contribution of the RAC1-PAK1 pathway underlying spinal hyperreflexia with SCI-induced spasticity, a feasible druggable target has not been validated.
View Article and Find Full Text PDFHistone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis.
Oncol Rep
October 2024
Department of Hematology, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China.
Article Synopsis
- B-cell lymphoma is hard to treat because it can behave differently and doesn't always respond well to standard treatments.
- New treatments involving immunotherapy and drugs that stop cancer from avoiding the immune system, like blocking PD-1, are being explored, but some cancers, including B-cell lymphoma, may not respond to these options.
- A study tested a combination of two treatments—a drug called romidepsin and a PD-1 blocker—on mice with B-cell lymphoma and found that together, they worked better at fighting the cancer and boosting the immune system's ability to attack the tumors.
Unlabelled: Pancreatic ductal adenocarcinoma-(PDAC) needs innovative approaches due to its 12% 5-year survival despite current therapies. We show marked sensitivity of pancreatic cancer cells to the combination of a novel eIF4A inhibitor, des-methyl pateamine A (DMPatA), and a histone deacetylase inhibitor, romidepsin, inducing epigenetic reprogramming as an innovative therapeutic strategy. Exploring the mechanistic activity of this combination showed that with a short duration of romidepsin at low doses, robust acetylation persisted up to 48h with the combination, while histone acetylation rapidly faded with monotherapy.
View Article and Find Full Text PDFImprovement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma.
Cancer Innov
April 2024
Sarcoma Treatment Laboratory, Research Institute Nozaki Tokushukai Hospital Daito Osaka Japan.
Background: Synovial sarcoma (SS) is an fusion gene-driven soft tissue sarcoma with mesenchymal characteristics, associated with a poor prognosis due to frequent metastasis to a distant organ, such as the lung. Histone deacetylase (HDAC) inhibitors (HDACis) are arising as potent molecular targeted drugs, as HDACi treatment disrupts the SS oncoprotein complex, which includes HDACs, in addition to general HDACi effects. To provide further molecular evidence for the advantages of HDACi treatment and its limitations due to drug resistance induced by the microenvironment in SS cells, we examined cellular responses to HDACi treatment in combination with two-dimensional (2D) and 3D culture conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!